TILsOV
Phase NA Terminated
36 enrolled
Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
Phase 3 Terminated
358 enrolled
PRO1107 in Patients With Advanced Solid Tumors
Phase 1/2 Terminated
33 enrolled
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Phase 1 Terminated
10 enrolled
A Study of PHN-010 in Patients With Advanced Solid Tumors
Phase 1 Terminated
26 enrolled
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Phase 1/2 Terminated
73 enrolled
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
Phase 2 Terminated
7 enrolled 10 charts
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Phase 1 Terminated
250 enrolled
Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy
Phase 2 Terminated
19 enrolled
Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Phase 1 Terminated
18 enrolled 19 charts
A Phase 1 Study of [225Ac]-FPI-1434 Injection
Phase 1 Terminated
78 enrolled
Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors
Terminated
22 enrolled
(VELA) Study of BLU-222 in Advanced Solid Tumors
Phase 1 Terminated
50 enrolled
A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)
Phase 2 Terminated
36 enrolled 11 charts
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
Phase 2 Terminated
166 enrolled 43 charts
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Phase 1 Terminated
17 enrolled
A Study of PF-06873600 in People With Cancer
Phase 1/2 Terminated
155 enrolled 44 charts
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Phase 1/2 Terminated
8 enrolled 12 charts
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Phase 1/2 Terminated
137 enrolled 31 charts
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Phase 1 Terminated
25 enrolled
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Phase 1 Terminated
10 enrolled
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
Phase 1 Terminated
23 enrolled
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Phase 2/3 Terminated
600 enrolled
A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer
Phase 1 Terminated
58 enrolled
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Phase 1 Terminated
9 enrolled
ARTISTRY-7
Phase 3 Terminated
456 enrolled 19 charts
MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Phase 1 Terminated
1 enrolled 5 charts
T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
Phase 1/2 Terminated
6 enrolled 11 charts
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
Phase 1 Terminated
4 enrolled
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
Phase 1/2 Terminated
5 enrolled
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
Terminated
19 enrolled
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Phase 1 Terminated
11 enrolled
AM-003
Phase 1 Terminated
5 enrolled
A Study to Investigate LYL797 in Adults With Solid Tumors
Phase 1 Terminated
57 enrolled
START
Terminated
10 enrolled
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
Phase 1/2 Terminated
25 enrolled
Exercise Preconditioning in Ovarian Cancer
Phase NA Terminated
8 enrolled
AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 1/2 Terminated
12 enrolled 13 charts
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
Phase 1 Terminated
16 enrolled
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
Phase 1 Terminated
85 enrolled
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
Phase 1/2 Terminated
52 enrolled 33 charts
NIRAPK
Phase 4 Terminated
12 enrolled
Auranofin and Sirolimus in Treating Participants With Ovarian Cancer
Phase 2 Terminated
22 enrolled 9 charts
C4431001
Phase 1 Terminated
30 enrolled 20 charts
Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase 2 Terminated
1 enrolled 5 charts
A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
40 enrolled 20 charts
Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma
Phase 2 Terminated
16 enrolled 11 charts
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Phase 2 Terminated
54 enrolled 11 charts
Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
Phase 2 Terminated
7 enrolled
COMPASS
Phase 4 Terminated
89 enrolled 20 charts